相关实验视频

Updated: Jun 13, 2025

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

开发一种基于酸的瘤激活检查点抑制剂,用于癌症免疫治疗

Zhen Zhao¹, John Fetse¹, Umar-Farouk Mamani¹

¹Division of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, 2464 Charlotte Street, Kansas City, MO 64108, USA.

Acta biomaterialia

|December 24, 2024

概括

研究人员开发了一种新型的瘤激活纳米粒子,该纳米粒子在瘤中释放抗PD-L1. 这种向免疫治疗方法抑制瘤生长并减少不良事件,为癌症治疗提供了一个有希望的策略.

科学领域:

免疫治疗是一种免疫疗法.
纳米技术纳米技术
在瘤学瘤学.

背景情况:

基于抗体的检查点抑制剂在癌症免疫治疗中有效,但会导致与免疫相关的重大不良事件.
开发专门在瘤微环境中起作用的向疗法对于提高安全性和有效性至关重要.

研究的目的:

为了设计一种激活瘤的纳米粒子,能够将抗PD-L1分泌到瘤部位.
通过确保瘤特异激活,减少与检查点抑制剂相关的免疫相关不良事件.

主要方法:

一个短的抗PD-L1 (TR3) 被识别并通过矩阵金属蛋白酶-2 (MMP-2) 特定的裂解链接器和PEG链进行修改.
修改后的是自组装成状纳米颗粒 (TR3-M-NP),在它们的原生形式中是不活跃的.
用TR3-M-NP进行了治疗,其激活和疗效在瘤模型中进行了评估,重点是MMP-2介导裂变.

主要成果:

TR3-M-NP纳米粒子在正常组织中保持不活跃,但在瘤中被MMP-2特别分裂,释放出活跃的TR3.
瘤特异性激活导致显著抑制瘤生长.
与对照组相比,接受TR3-M-NP治疗的小鼠的生存时间延长,表明毒性降低.

结论:

TR3-M-NP是一种新型瘤反应性免疫疗法剂,具有减轻免疫相关不良事件的潜力.
这种基于的纳米粒子平台在向癌症治疗方面显示出显著的前景,并且可以适应其他检查点抑制剂.

关键词:

抗PD-L1的抗PD-L1 的这是一种类.自组装的纳米粒子由瘤激活的免疫疗法.

更多相关视频

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...